Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 3 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Post Marketing Clinical Research Introduction | 7 | 1 |
| GBI Research Report Guidance | 7 | 1 |
| Post Marketing Clinical Research: Overview | 8 | 6 |
| Introduction | 8 | 1 |
| Objectives of Post Marketing Clinical Research | 9 | 1 |
| Establishing Safety through Clinical Trials | 9 | 1 |
| Pre-Approval Drug Safety | 9 | 1 |
| Post Marketing Drug Safety | 10 | 1 |
| Establishing Efficacy through Clinical Trials | 10 | 1 |
| Limitations of Phase I to Phase III Clinical Trials | 11 | 1 |
| Pharmaceutical Industry and Drug Safety Challenges | 12 | 1 |
| Post Marketing Clinical Research: an Unavoidable Necessity for the Pharmaceutical Industry | 13 | 1 |
| Phase IIIb Studies - Tool to Improve Revenues | 13 | 1 |
| Post Marketing Clinical Research-Promotes Public Health in Large Populations | 13 | 1 |
| Post Marketing Clinical Research: Objectives and Components | 14 | 21 |
| Introduction | 14 | 1 |
| Objectives of Post Marketing Clinical Research | 14 | 1 |
| Promoting Public Health | 14 | 1 |
| Rational Use of Drugs | 14 | 1 |
| Assessment of Side Effects | 15 | 1 |
| Long Term Safety and Efficacy | 16 | 1 |
| Assessing Long Term Pharmacokinetics | 16 | 1 |
| Designing Public Health Policies | 17 | 1 |
| Market Development | 18 | 1 |
| Impact of Post Marketing Surveillance on Life Cycle Management | 18 | 1 |
| Indication Expansion | 19 | 1 |
| Formulary Access | 19 | 1 |
| Product Positioning | 20 | 1 |
| Components of Post Marketing Clinical Research | 21 | 1 |
| Risk Evaluation and Mitigation Strategies (REMS) | 22 | 1 |
| Objectives of REMS | 22 | 1 |
| Importance of REMS | 22 | 1 |
| Components of REMS | 23 | 1 |
| Pharmacoeconomics | 24 | 1 |
| Introduction | 24 | 1 |
| Types of Pharmacoeconomic Research | 25 | 1 |
| Impact of Pharmacoeconomics | 26 | 1 |
| Health Technology Assessment | 26 | 1 |
| Pharmacoepidemiology | 27 | 1 |
| Epidemiology Study Designs | 27 | 2 |
| Application of Pharmacoepidemiology to Post Marketing Clinical Research | 29 | 1 |
| Pharmacovigilance | 29 | 1 |
| Introduction | 29 | 1 |
| Objectives | 29 | 1 |
| Importance of Pharmacovigilance | 30 | 1 |
| Factors Influencing Pharmacovigilance | 30 | 1 |
| Safety Signal and its Detection | 31 | 3 |
| Limitations of Pharmacovigilance | 34 | 1 |
| Post Marketing Clinical Research in Special Groups | 35 | 20 |
| Post Marketing Studies in Different Population Groups | 35 | 1 |
| Children | 35 | 1 |
| Issues of Drug Safety in Children | 35 | 1 |
| Pediatric Provisions in FDA Amendments Act 2007 | 35 | 1 |
| Pediatric Initiatives in Europe | 35 | 2 |
| Drug Safety Surveillance Strategies in Children | 37 | 1 |
| Elderly | 37 | 1 |
| Issues of Drug Safety in Elderly | 37 | 1 |
| Impact of Adverse Drug Reactions (ADRs) in the Elderly | 37 | 1 |
| Pharmacodynamics in the Elderly | 38 | 1 |
| Pharmacokinetics in the Elderly | 38 | 2 |
| Pregnancy | 40 | 1 |
| Drug Labeling and Pregnancy | 40 | 1 |
| Post Marketing Surveillance Strategies in Pregnant Women | 41 | 2 |
| Post Marketing Studies in Different Therapy Areas | 43 | 1 |
| Oncology Therapeutics | 43 | 1 |
| Accelerated Approval and Oncology Therapeutics | 43 | 1 |
| Cardiovascular Therapeutics | 44 | 1 |
| Central Nervous System Therapeutics | 45 | 1 |
| Gene Therapy | 45 | 1 |
| Gene Therapy: Basic Process | 45 | 1 |
| Types of Gene Therapy | 46 | 1 |
| Post Marketing Surveillance of Gene Therapy | 46 | 1 |
| Post Marketing Studies in Different Drug Classes | 47 | 1 |
| Orphan Drugs | 47 | 1 |
| Vaccines | 48 | 1 |
| Pharmacovigilance of Vaccines | 49 | 1 |
| Anti-HIV Drugs | 50 | 1 |
| Methods of Drug Safety Monitoring of Anti-HIV Drugs | 50 | 1 |
| Monoclonal Antibodies | 51 | 2 |
| Blood Products | 53 | 1 |
| Hemovigilance in Europe | 53 | 1 |
| Hemovigilance in the US | 53 | 1 |
| Challenges of Hemovigilance in the US | 54 | 1 |
| Post Marketing Clinical Research - Regulatory Landscape | 55 | 20 |
| WHO Approach to Drug Safety | 55 | 1 |
| WHO Programme for International Drug Monitoring | 55 | 1 |
| Uppsala Monitoring Centre (UMC) | 55 | 1 |
| Functions of UMC | 55 | 1 |
| ICH-GCP and Post Marketing Clinical Research | 56 | 1 |
| Drug Safety Regulations in the US | 57 | 1 |
| FDA Amendment Act (FDAAA) | 57 | 1 |
| Prescription Drug User Fee Amendments, 2007 | 57 | 1 |
| Medical Device User Fee Amendments, 2007 | 57 | 1 |
| Pediatric Research Equity Act, 2007 | 57 | 1 |
| Best Pharmaceuticals for Children Act, 2007 | 57 | 1 |
| Clinical Trial Databases | 58 | 1 |
| Enhanced Authorities Regarding Post Market Safety of Drugs | 58 | 1 |
| Implications of FDAAA on Pharmaceutical Industry | 59 | 1 |
| Role of FDA in Promoting Drug Safety | 59 | 1 |
| Adverse Event Reporting System | 60 | 2 |
| Drug Withdrawals from the US Market | 62 | 1 |
| Drug Safety Regulations in Europe | 62 | 1 |
| Incidences of Adverse Events in Europe | 62 | 1 |
| Safety Regulations in Europe | 62 | 1 |
| European Risk Management Strategy | 63 | 1 |
| EudraVigilance | 63 | 1 |
| EudraVigilance Signal Detection Methods | 63 | 1 |
| Drug Safety Regulations in Europe and the US | 64 | 1 |
| Similarities of Drug Safety Regulations in the US and the EU | 64 | 1 |
| Regulations in the EU and the US: Challenges and Advantages | 64 | 1 |
| Regulations in the EU and the US: New Risk Management Initiatives | 65 | 1 |
| Drug Safety Regulations in Japan | 66 | 1 |
| Pharmaceuticals and Medical Devices Agency | 66 | 1 |
| Application of Data Mining in Safety Surveillance | 66 | 1 |
| Application of Electronic Records in Safety Surveillance | 66 | 1 |
| Good Post Marketing Surveillance Practice | 66 | 1 |
| Good Post Marketing Study Practice | 67 | 1 |
| Good Vigilance Practice | 67 | 1 |
| Adverse Drug Reaction Reporting System | 68 | 1 |
| Adverse Event Reporting by Medical Personnel | 68 | 1 |
| Adverse Event Reporting by Pharmaceutical Companies | 69 | 1 |
| Re-Examination and Re-Evaluation System | 70 | 1 |
| Drug Safety Regulations in Emerging Markets | 71 | 1 |
| Drug Safety Regulations in China | 71 | 1 |
| The National Center for Adverse Drug Reaction Monitoring | 71 | 1 |
| Drug Safety Regulations | 71 | 1 |
| Drug Safety Regulations in Brazil | 72 | 1 |
| Pharmacovigilance Unit | 72 | 1 |
| Functions of Pharmacovigilance Unit | 72 | 1 |
| Drug Safety Regulations in Russia | 73 | 1 |
| Drug Safety Regulations | 73 | 1 |
| Drug Safety Regulations in India | 73 | 1 |
| National Pharmacovigilance Programme | 73 | 2 |
| Post Marketing Clinical Research and Outsourcing | 75 | 3 |
| Introduction | 75 | 1 |
| Advantages of Outsourcing | 75 | 1 |
| Selection of Outsourcing Partners | 76 | 1 |
| Phase IV Outsourcing | 76 | 1 |
| Limitation of Outsourcing | 77 | 1 |
| Post Marketing Clinical Research - Appendix | 78 | 5 |
| Market Definitions | 78 | 1 |
| Abbreviations | 78 | 2 |
| Research Methodology | 80 | 2 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 81 | 1 |
| Expert Panel Validation | 81 | 1 |
| Contact Us | 81 | 1 |
| Disclaimer | 81 | 1 |
| Sources | 82 | 1 |